ITM Solucin GmbH   Report issue

For profit Phase 3
Founded: Munich Germany (2004)

Organization Overview

First Clinical Trial
2017
NCT03049189
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ITM Solucin GmbH

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neuroendocrine Tumors (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 8